Talquetamab in Heavily Pretreated Multiple Myeloma Patients, Including BCMA-Refractory

Andrew J Vegel; Bradley T Loeffler; Jonathan Lochner; Reed Friend; Alma Habib; Marshall Mckenna; Jordan Snyder; Kimberly Green; Rachel Dileo; Gina Patrus; Prerna Mewawalla; Muhammad Umair Mushtaq; Christopher Strouse; Yun Kyoung Ryu Tiger; Nausheen Ahmed; Abdullah M. Khan; Hamza Hashmi; Barry Paul; Shebli Atrash; Al-Ola Abdallah; Hira Shaikh

doi:10.1016/j.bict.2025.100001

Back

$Talquetamab in Heavily Pretreated Multiple Myeloma Patients, Including BCMA-Refractory$

Journal article

Open access

Peer reviewed

Talquetamab in Heavily Pretreated Multiple Myeloma Patients, Including BCMA-Refractory

Andrew J Vegel, Bradley T Loeffler, Jonathan Lochner, Reed Friend, Alma Habib, Marshall Mckenna, Jordan Snyder, Kimberly Green, Rachel Dileo, Gina Patrus, …

Blood Immunology & Cellular Therapy, Vol.1(1), 100001

06/2025

DOI: 10.1016/j.bict.2025.100001

Files and links (1)

url

https://doi.org/10.1016/j.bict.2025.100001View

Published (Version of record) Open Access

Abstract

Talquetamab is a G protein-coupled receptor class C group 5 member D (GPRC5D) targeting bispecific T-cell engager (TCE) approved for patients with relapsed multiple myeloma based on the MonumenTAL-1 trial. In this retrospective study of 68 patients, we evaluated safety and efficacy of talquetamab in a real-world population across seven US academic centers. We found that 40% of patients would have been ineligible for MonumenTAL-1 trial. Infections (29%) were far less common than in MonumenTAL-1 and with the BCMA-directed therapies (BDT). Cytopenias and unique toxicities of talquetamab such as dysgeusia (78%) were more frequent than in MonumenTAL-1, while other side effects were comparable. The best overall response rate (ORR) was 71%, with 51% ≥ very good partial response and 25% ≥ complete response. At a median follow-up of 4.6 months (95% CI, 0.5–17.5), estimated 6-month OS was 74% (95% CI 59-85). On multivariate analysis, prior bispecific antibody exposure (HR 3.87, p=0.01) and extramedullary disease (HR 2.81, p<0.01) were associated with worse progression-free survival (PFS). In the BCMA-exposed group (n=63), BDT immediately preceding talquetamab was associated with lower ORR (48% vs 81%, p=<0.01) and shorter PFS (HR 2.10, p=0.04). Similarly, BDT within 6 months of talquetamab negatively affected ORR (57% vs 85%, p=0.02), PFS (HR 2.3, p=0.03) and OS (HR 4.8, p=0.04). Overall, the safety and efficacy profile of talquetamab in this real-world dataset are similar to the MonumenTAL-1 trial.

Details

Title: Subtitle: Talquetamab in Heavily Pretreated Multiple Myeloma Patients, Including BCMA-Refractory
Creators: Andrew J Vegel - University of Iowa
Bradley T Loeffler - University of Iowa
Jonathan Lochner - University of Iowa
Reed Friend
Alma Habib
Marshall Mckenna
Jordan Snyder
Kimberly Green
Rachel Dileo
Gina Patrus
Prerna Mewawalla
Muhammad Umair Mushtaq
Christopher Strouse - University of Iowa
Yun Kyoung Ryu Tiger
Nausheen Ahmed
Abdullah M. Khan
Hamza Hashmi
Barry Paul
Shebli Atrash
Al-Ola Abdallah
Hira Shaikh - University of Iowa
Resource Type: Journal article
Publication Details: Blood Immunology & Cellular Therapy, Vol.1(1), 100001
DOI: 10.1016/j.bict.2025.100001
ISSN: 3050-5976
Language: English
Electronic publication date: 04/2025
Date published: 06/2025
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984808277102771

Metrics

81 Record Views